Publications by authors named "C M Boesjes"
Increasing dosing intervals for biologics in atopic dermatitis-why, who, when and how?
J Eur Acad Dermatol Venereol
January 2025
Biologics approved and in development for atopic dermatitis offer life-changing clinical efficacy with a relatively banal long-term safety profile requiring no laboratory monitoring. Biologic therapies also have their drawbacks, including high payor cost and the need to be administered as every other week subcutaneous injections. Addressing these concerns, studies of longer dosing intervals have been performed in the formal clinical trial setting and during real-world clinical care.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the long-term effectiveness and safety of dupilumab, a treatment for atopic dermatitis (AD), in a diverse group of patients over a period of up to 5 years.
- Conducted in the Netherlands using the BioDay registry, the research includes 1,286 patients of different age groups receiving dupilumab between 2017 and 2022, with outcomes evaluated using various clinical measures.
- Results show that a majority of patients maintained controlled AD symptoms, with high levels of treatment effectiveness observed over time, and factors for treatment discontinuation were also assessed.
Article Synopsis
- A study evaluated the effectiveness and safety of dupilumab for treating moderate-to-severe atopic dermatitis (AD) over a long-term period of up to 5 years, emphasizing patient-reported outcomes.
- Data from 1223 patients (1108 adults and 115 children) showed improved quality of life measures and work impairment in both groups after at least one year of treatment.
- Despite the treatment's favorable safety profile, including a 66.8% reporting rate of adverse events (most commonly conjunctivitis), there were significant amounts of missing data in reported outcomes, particularly in children.
Article Synopsis
- * Out of 103 patients, significant improvements were observed over 28 weeks, with high rates of reduction in eczema severity and itching.
- * While some patients discontinued due to ineffectiveness or adverse events (mainly nausea), abrocitinib showed effectiveness for those who previously did not respond to other treatments like dupilumab or upadacitinib.
Article Synopsis
- Pathogenic variants in the filaggrin (FLG) gene are linked to a higher risk of developing atopic dermatitis (AD), prompting this study to explore how these variants affect dupilumab treatment outcomes.
- A total of 285 adult patients with AD were assessed for FLG variants and treatment effectiveness using various measures at the start and after 16 and 52 weeks of treatment.
- The findings revealed that dupilumab's effectiveness was similar for patients with and without pathogenic FLG variants, but those with biallelic variants reported worse skin dryness and flaking over time compared to others.